CT23-02

Prolonged cytopenia after Idecabtagene Vicleucel for multiple myeloma is associated with poor overall survival.

Citation

Kaur G, Logue J, Brazauskas R, Oloyede T, Abid MB, Ahmed S, Aljurf M, Banerjee R, Bashey A, Beitinjaneh AM, Callander NS, Castillo P, Dholaria B, Goldsmith SR, Hashmi S, Kharfan-Dabaja MA, Liu H, Mian H, Nishihori T, Rejeski K, Saad A, Slade MJ, Turtle CJ, Vogl DT, Williams KM, Wirk B, Pasquini MC, Moskop A, Akhtar OS, Hansen DK, Janakiram M.

Transplantation and Cellular Therapy. 2026, Nov 01: 32(11): 32(11):1428.e1-1428.e16. doi: 10.1016/j.jtct.2026.06.021. Epub 2026, Jun 16. PMCID:PMC13560755.

PubMed

PMID: 42302965

Abstract